Abstract Number: 1163 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Radiologic Progression in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Background/Purpose: Progression of joint damage is sometimes observed in JIA patients during the biologic therapy. However, it is difficult to evaluate the radiographic progression by…Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting
Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study
Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…Abstract Number: 2172 • 2012 ACR/ARHP Annual Meeting
An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection in the Southwestern United States which typically causes a self-limited pulmonary illness. Patients with rheumatic disease…Abstract Number: 1142 • 2012 ACR/ARHP Annual Meeting
Efficacy of Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review Using Indirect Comparisons
Background/Purpose: During the last decade the availability of biologic agents for the treatment of juvenile idiopathic arthritis (JIA) increased substantially. Because direct head-to-head trials comparing…Abstract Number: 2155 • 2012 ACR/ARHP Annual Meeting
The Annualized Progression of Radiologic Damage in Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower Than the Mean Annual Progression Since Disease Onset
Background/Purpose : A previous meta-analysis by Graudal and Jürgens (Arthritis Rheum. 2010;62:2852–63) challenged the belief that biologics better protect rheumatoid arthritis (RA) from joint destruction…Abstract Number: 1145 • 2012 ACR/ARHP Annual Meeting
Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results From the Biologics for Children with Rheumatic Diseases Study
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologic therapy, although the majority remain unlicensed for children. Until…Abstract Number: 2093 • 2012 ACR/ARHP Annual Meeting
Rates of Opportunistic Infections Among Rheumatoid Arthritis Patients Switching Biologic Therapy
Background/Purpose: The incidence of opportunistic infections (OIs) in patients on biologics is low, but may approach several cases per 100 person-years (PY). Data on risks…Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting
Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists
Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…Abstract Number: 2055 • 2012 ACR/ARHP Annual Meeting
TEAM-Managed Care of Biological Patients At A Canadian Centre
Background/Purpose: Managing complex arthritic patients with biologics is exacting and time consuming. As a result in January 2008 we established a separate biologic clinic with…Abstract Number: 1004 • 2012 ACR/ARHP Annual Meeting
A Unique Single Nucleotide Polymorphism in the 3’ UTR of the MED29 Gene On Chromosome 19 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers
Background/Purpose: Due to the wide range of highly specific and effective biologic response modifiers that are available today for the treatment of RA it has…
- « Previous Page
- 1
- …
- 4
- 5
- 6